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Background: As Chronic Fatigue Syndrome (CFS) has been known to follow Epstein-Bar virus (EBV) and other
systemic infections; our objective was to describe differences in immune activation in post-infective CFS (PI-CFS)
patients and recovered controls. We studied 301 adolescents prospectively over 24 months following the diagnosis
of monospot-positive infectious mononucleosis (IM). We found an incidence of CFS at 6, 12 and 24 months of 13%,
7% and 4% respectively.
Methods: Using chemiluminescent imaging we measured the concentrations of IL-1a, 1b, 2, 4, 5, 6, 8, 10, 12 (p70),
13, 15, 17 and 23, IFN-γ, TNF-α and TNF-β in duplicate plasma samples available in bio-bank from 9 PI-CFS subjects
and 12 recovered controls at 24 months post-infection.
Results: Standard comparative analysis indicated significant differences in IL-8 and 23 across subject groups. In
constructing a linear classification model IL-6, 8 and 23 were selected by two different statistical approaches as
discriminating features, with IL-1a, IL-2 and IFN-γ also selected in one model or the other. This supported an
assignment accuracy of better than 80% at a confidence level of 0.95 into PI-CFS versus recovered controls.
Conclusion: These results suggest that co-expression patterns in as few as 5 cytokines associated with Th17
function may hold promise as a tool for the diagnosis of post-infectious CFS.
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Chronic Fatigue Syndrome (CFS) is a complex and
poorly understood illness that affects between 1 and 4
million individuals [1,2] and costs an estimated $35 bil-
lion per year in lost productivity and health care [3,4].
Persistent and unexplained fatigue has been observed as
a sequela of acute infection since the first half of the
20th century and the period’s notable outbreaks of infec-
tious disease (e.g., polio epidemics, influenza pan-
demics). From 1934 to 1984, there were several reports
of infectious disease outbreaks simulating poliomyelitis
[5,6] though no causal pathogen was isolated from the
majority of the cases. Clinical investigation of individuals
who did not recover several years after initial infec-
tion showed persistent symptoms of fatigue, sleep* Correspondence: gordon.broderick@ualberta.ca
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reproduction in any medium, provided the ordisturbance and cognitive impairment [7,8]. Following
an outbreak investigation in 1984 by the Centers for
Disease Control and Prevention (CDC) in Incline
Village, Nevada [9], an international group of medical
experts defined this protracted post-infection illness as
chronic fatigue syndrome (CFS) [10]. Since then, post-
infection illness that lasts for more than six months is a
central component of CFS, and studies have shown that
the incidence of CFS following infection with a number
of different pathogens is about 10% [11-14]. The patho-
gens that most commonly lead to CFS in prospective
studies are those that cause infectious mononucleosis
(IM)/glandular fever (mainly Epstein-Barr virus (EBV);
occasionally cytomegalovirus (CMV), human herpesvirus
6, hepatitis A, and adenovirus [11], Q fever and Ross
River virus (mainly in Australia [13]), enteroviruses [15]
and parvovirus B19 [16,17]. Indeed in recent work by
Kerr and colleagues, antibody testing for EBV, entero-
virus, Coxiella burnetii (causative agent of Q fever) andal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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relationships for EBV and enterovirus, two of the most
common infectious triggers of CFS/ME [18].
There remains therefore an overwhelming body of evi-
dence reinforcing the link to an infectious etiology in at
least a subset of CFS patients, despite the fact that spe-
cific viral serology are not required for diagnosing CFS
[19,20]. Specifically, there is a notable and long-standing
association of CFS with EBV infection. In our previously
published analyses of the adolescent cohort presented
here [14,21-24], we reported a diagnosis of CFS at 6, 12
and 24 months following IM, in 13%, 7% and 4%, of the
subjects respectively. Ninety percent of CFS subjects at 6
months were female as were all cases at 12 (n = 22) and
24 (n = 13) months following IM. This is consistent with
the rates observed by Buchwald and colleagues (2000)
[12] who found 12% of subjects had not recovered and
were reporting symptoms of fatigue and impaired func-
tioning 6 months following onset of IM, 76% of whom
were female. Nearly identical results were also reported
in an Australian cohort where 11% and 9% of subjects
satisfied the case definition for CFS at 6 and 12 months
following onset of IM, Q fever and Ross River fever
(RRF) [13].
Investigators have sought to understand the underlying
causes of these persistent symptoms by surveying im-
mune signaling in the CFS patient population. Early
measurements of cytokine concentrations in blood sam-
ples from this broader population produced widely dis-
cordant results due mainly to differences in case
definition and laboratory protocols [25]. Limiting factors
also include the focus on a varied and narrow selection
of cytokines [26] as well as a conventional univariate
analysis that does not account for the context-specific
expression of cytokines [27]. Only one previous study
has prospectively evaluated cytokine production in CFS
patient populations where a uniform infectious trigger
was supported by serology. Hickie et al. (2006) [13] mea-
sured the concentrations of 8 cytokines: IL-1b, IL-2, IL-
4, IL-6, IL-10, IL-12, TNF-α, and IFN-γ in serum and
culture supernatants of peripheral blood mononuclear
cells collected 1, 2, 3, 6 and 12 months following the
acute illness (IM, RRF or Q fever). The participants were
22 subjects with confirmed PI-CFS (11 EBV, 6 RRV, and
5 Q fever) and 42 control subjects (17 EBV, 14 RRV, and
11 Q fever) matched for age from the same cohort who
had recovered within 6 weeks of symptom onset. The
analyses were performed on all PI-CFS subjects as a sin-
gle group, combining the 11 EBV patients with those
infected by a virus uncommon outside Australia. They
found no significant differences between PI-CFS cases
and recovered controls in serum or culture supernatants
[28]. However, serum cytokine levels were almost exclu-
sively below the assay detection limit (8–15 pg/ml) andsupernatants were cultured from cryopreserved PBMCs.
As a result several unanswered questions remain. For
example, do key CFS-specific cytokines remain unmeas-
ured? Perhaps most importantly, could PI-CFS cytokine
signatures reflect pathogen-specific (and gender-specific)
variations in immune response? If so these may be lost
when pooling subjects with different infectious triggers
(and different genders).
In an attempt to address some of these questions, this
secondary analysis has focused specifically on a group of
female adolescents diagnosed PI-CFS as the result of a
uniform and known pathogen, namely EBV. An
extended survey of 16 cytokines was conducted in
plasma using a modified chemiluminescent assay [27]
and identified significant differences in IL-8 and IL-23
concentrations in the patient group at 24 months
post-infection. Because cytokines are expressed in a coor-
dinated fashion we also extended the analysis beyond the
traditional univariate analysis to investigate combinatorial
effects across multiple cytokines. Taken together, a classifi-
cation of subjects based on levels of IL-2, 6, 8 and 23 sup-
ported assignment into the patient or control group with
an accuracy exceeding 80% when applied relative to inter-
feron gamma (IFN-γ) concentration. Interestingly the latter
did not differ significantly in expression level across subject
groups.
Methods
Cohort and clinical assessment
The cohort consisted of 301 adolescents recruited from
the greater Chicago area upon diagnosis of monospot-
positive acute IM, the presumption being that the vast
majority of these cases were caused by EBV infection.
Details of this cohort may be found in a recent report by
Katz et al. (2009) [14]. In brief, adolescents were identi-
fied via school nurses (middle school, high school and
college/university), pediatric practices, including the
Pediatric Practice Research Group and the Virology La-
boratory of Children’s Memorial Hospital. All prescribed
treatments were recorded. Six months following their
IM diagnosis, 286 (95%) subjects completed a telephone-
based screening interview using the CFS Screening
Questionnaire [29]. Based on the screening interview, 70
of these adolescents (24%) were assessed as not fully
recovered. A clinical evaluation was completed on 53
(76%) of these 70 not fully recovered adolescents; 12
refused, 3 had exclusionary diagnoses and 2 did not
meet study criteria. There was no significant difference
in sex, family socioeconomic status or subject age be-
tween the group that completed the 6-month evaluation
(n = 53), the group (n = 12) that refused and the group
(n = 5) that was excluded (data not shown). Following
the 6-month clinical evaluation, 39 of the 53 not fully
recovered subjects who underwent clinical evaluation
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of 301 adolescents). Compared with the other 262 en-
rolled subjects in the cohort, 35 of the 39 subjects with
CFS at 6 months were female (90%, vs 68%, p = 0.01 by
Fisher’s exact test). There was no difference in race or
socioeconomic status between the entire cohort and the
subjects who went on to develop CFS (data not shown).
Among the 14 other subjects completing the 6-month
clinical evaluation, 1 had recovered between the time of
the phone interview and the time he/she was seen in
clinic and 13 were classified as CFS explained. There
was no difference in family socioeconomic status or sub-
ject age between the group diagnosed with CFS (n = 39)
and the group (n = 13) with CFS-explained (data not
shown).
Thirty-six subjects diagnosed with CFS at the 6-month
evaluation were re-evaluated at 12 months (3 were lost
to follow-up): 11 recovered, 3 were now classified as
CFS-explained, leaving 22 with a diagnosis of CFS (7%
of the original sample; all females). At the 24-month
evaluation, 3 more subjects with CFS were lost to
follow-up since the 12-month evaluation. Of the 19
remaining subjects diagnosed with CFS at 12 months: 6
more recovered, 2 developed a reason for their CFS, 1
subject thought to have recovered at 12 months devel-
oped symptoms again and was reclassified as CFS, and 1
subject thought to have CFS-explained at 12 months
now met criteria for CFS and had no predisposing rea-
son, leaving 13 subjects (all females) who were classified
as CFS 24 months following monospot-positive IM (4%
of the original sample of 301 adolescents). Following the
IM diagnosis, a telephone-screening interview also iden-
tified 50 recovered controls willing to come for a clinical
evaluation. Adolescents who had not fully recovered and
recovered controls underwent evaluation 6, 12 and 24
months post-IM. There was no difference in age, race or
socioeconomic status between recovered adolescents
who were and were not used as controls subjects (data
not shown). At the 6-month evaluation recovered and
non-recovered subjects were evaluated by 1 of 2 physi-
cians experienced in diagnosing CFS (BZK or an adoles-
cent specialist). At the 12 and 24-month visits, the
subjects were evaluated in their home with the same
blood and urine testing and the same history, interviews,
and self-report measures used at six months, by a
trained interviewer. All aspects of the study were
approved by the Institutional Review Boards of Chil-
dren’s Memorial Research Center and the College of Ap-
plied Sciences of the University of Illinois at Chicago.
Secondary analysis of the biological samples and data
was reviewed and approved by the Institutional Review
Board of the University of Alberta. Diagnosis of CFS was
based on the revision by Jason et al. (2006) [30] of the
international CFS case definition [20], itself a revision ofthe of the Fukuda criteria [19], although all patients also
met the international case definition of CFS [20]. When
a well-recognized underlying condition such as primary
depression could explain a subject’s symptoms then that
subject was classified as having “CFS-explained”, and
these subjects were not included in the analysis. Primary
depression was defined based on the Structured Clinical
Interview for the DSM-IV Child Version.
The clinical evaluation included laboratory tests to
rule out medical causes of CFS (e.g., chemistry panel,
complete blood count, erythrocyte sedimentation rate,
liver chemistries, urine toxicology, urinalysis and thyroid
function tests). The examining physician at 6 months
made a diagnosis of CFS, CFS-explained, or recovered
on each subject. These diagnoses were then blindly
reviewed by an expert panel using the Jason revision for
pediatrics [30] of the Fukuda criteria [19] before being
permanently assigned to a subject. Each subject also
completed the Chalder Fatigue Scale at 6, 12 and 24
months [31], along with the Youth Medical Question-
naire, Modifiable Activity Questionnaire, Sleep Assess-
ment Questionnaire, and the Structured Clinical
Interview for the DSM-IV Child Version, Child/Young
Adult Behavior Checklist, Child/Young Adult Self-Re-
port, and Life Events and Difficulty Questionnaire [30].
At 24-months post-IM onset, 13 subjects satisfied the
criteria for CFS, all of whom were young women. Plasma
samples were available for n = 9 of these 13 CFS patients
24-months after diagnosis with IM and 12 recovered
controls, matched as closely as possible to the subjects
with CFS by gender, age (+/- 1 year) and Tanner stage (4
or 5).
Laboratory measurements
Morning fasting blood samples were collected into ethyl-
ene diamine tetra acetic acid (EDTA) anticoagulant
tubes. Plasma was separated within 2 hours of collection
and stored at -80oC until assayed. We measured 16 cyto-
kines in plasma using Quansys reagents and instrument
(Quansys Biosciences, Logan, Utah) in the same way as
reported previously in a larger cohort of CFS subjects
with unknown etiology and illness trigger [26]. The
Quansys Imager, driven by an 8.4 megapixel Canon
20D digital SLR camera, supports 96 well plate
based chemiluminescent imaging. The Q-Plex™ Human
Cytokine - Screen (16-plex) is a quantitative enzyme-
linked immunoabsorbent assay (ELISA)-based test where
sixteen distinct capture antibodies have been absorbed
to each well of a 96-well plate in a defined array. The
range of the cytokine concentrations used in the stand-
ard calibration samples were adjusted for each cytokine
along with sample exposure time to provide the most re-
liable comparison possible between CFS patients and
controls across the range of cytokine concentrations
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we used the second order (k = 2) polynomial regression
model (parabolic curve): Yp = b0 + b1X1 + b2X2.... + bkXk,
where Yp is the predicted outcome value for the polyno-
mial model with regression coefficients b1 to bk for each
degree and y intercept b0. The standard sample concen-
trations used to establish the calibration curves for each
cytokine are listed in Additional file 1: Table S1; these
confirm that the concentrations reported in study sub-
jects are within the calibrated range for this assay.
Statistical analyses
Comparative statistics
Each plasma sample was run in duplicate. To compare
subject-to-subject variation with replicate error both the
parametric n-way ANOVA and the nonparametric
Kruskall-Wallis tests were used. Results presented in
Additional file 1: Table S2 indicate that variations separ-
ating individuals was statistically greater than replicate
error for most cytokines in at least one subject group or
the other. The parametric n-way ANOVA applied to
log-transformed values was generally more sensitive to
these differences than the Kruskall-Wallis test. Replicate
error in the measurement of IL-1a, IL-10 and IL-17 did
not support subject-to-subject resolution within either
group regardless of the statistical test used. These were
nonetheless adequate for use in comparisons across pa-
tient groups as a whole.
To assess the significance of differences in the mean
expression of individual cytokines separating subject
groups we used a standard parametric t test after per-
forming a logarithmic transformation. In conjunction
with this a nonparametric Wilcoxon rank-sum test was
used to compare the difference in group-wise median
expression for each cytokine. Values below detection
limit were replaced with the lowest concentration
recorded for each specific cytokine within each subject
group.
Classification analysis
As an extension of this group-wide analysis of expres-
sion levels, cytokines were ranked according to their
classification of individual subjects based on their asso-
ciated receiver operating characteristic (ROC) curves
and on the U-statistic of a two-sample unpaired Wil-
coxon ranksum test. In addition to an unadjusted rank-
ing, a relative ranking was also computed that accounted
for the cross-correlation (CC) existing between individ-
ual cytokines. In this adjustment correlation information
was used to reweight the Z value of a candidate cytokine
using Zi (1-α ‾r ij), where ‾rij is the average of the abso-
lute values of the cross-correlation coefficient between
the candidate i and all previously selected cytokines j = 1
through i. The weighting factor α (alpha) is a scalarvalue between 0 and 1. According to this adjustment a
large value of ‾rij outweighs the significance statistic Z
making new candidates that are highly correlated with
previously ranked cytokines less likely to be selected
next.
The use of cytokines in combination with one another
was also considered. For this, linear discriminant classifi-
cation models were constructed iteratively using ran-
domly selected subsets of cytokines and their
performance evaluated. All cytokines were normalized to
have a mean value of 0 and a variance of 1.0. Classifiers
were evaluated based on their overall error rate (incor-
rectly classified samples / total classified samples) in
assigning subjects to their proper diagnostic group. Only
classifiers with overall error rate of less than 20% were
accepted into the pool of candidates. In addition the
posterior probability of the discriminant analysis was
used to invalidate candidate class assignments with low
confidence (< 0.90) and label any such instance as an in-
conclusive classification. Furthermore a strict linear clas-
sification model was selected to favor subsets of
cytokines that were minimally redundant. Traditional or-
dinary least squares models will perform poorly when
correlated or collinear terms are used together due to
variance inflation [32]. Final correction of the linear clas-
sifier for collinearity in the selected cytokine subsets was
performed using a diagonal covariance matrix estimate.
According to this model an observed row x from the
sample array is classified into group I rather than group
J if 0 < B0 + x*B, where the coefficient vector B and inter-
cept vector B0 are estimated from the data.
In order to assess the robustness of models con-
structed using the all-possible-subsets approach
described above, an analysis of this data using a sequen-
tial stepwise variable selection [33] was also conducted.
Using this algorithm, a linear classification model was
constructed by selecting cytokines sequentially based on
their respective partial-F test values. Cytokines with a p
(partial F) < 0.05 were selected for recruitment into the
regression model while those currently in the model but
showing a p(partial F) > 0.10 were pruned. All calcula-
tions described above were performed using the classify,
classperf, rankfeatures, randfeatures and stepwisefit
functions available in the MatLab Statistics Toolbox and
the MatLab Bioinformatics Toolbox (The MathWorks,
Inc., Natick, MA).
Results
Cytokine expression in PI-CFS patients
Summary statistics for group-wise expression of cyto-
kines in PI-CFS patients and subjects who recovered
normally from IM are presented graphically in Figure 1
(see also Additional file 1: Table S3). Briefly these show
that IL-8 was significantly elevated in median expression
Figure 1 Cytokine Expression in Post-mononucleosis Chronic Fatigue. Cytokine Expression Median concentration (with median absolute
deviation from median) of 16 cytokines measured in peripheral blood plasma from n= 12 adolescents recovering normally at 24 months from
infectious mononucleosis (IM) and n= 9 patients suffering from post-infectious chronic fatigue syndrome (PI-CFS).
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decreased. We also found IL-2 expression to be elevated
in PI-CFS though this reached statistical significance for
the t-test only. Similarly reduced expression of IL-5 in
PI-CFS was significant based on the Wilcoxon rank sum
test only. A trend towards increased IL-13 expression
was also observed (p ~ 0.07).
Ranking individual cytokine markers
Univariate analysis indicated that cytokines IL-2, IL-5,
IL-8 and IL-23 were significantly different, in either
mean or median expression, in PI-CFS patients com-
pared to subjects that had recovered. To investigate
these differences we estimated how individual cytokines
might rank on the basis of their performance in
assigning subjects to the correct diagnostic class, namely
PI-CFS or recovered controls. As expected, the results
presented in Table 1 indicate that as individual biomar-
kers IL-5, IL-8 and IL-23 ranked consistently in the top
3 positions based on both the area under the receiver
operating characteristic curve (AUC) and the Wilcoxon
U statistic. In terms of AUC, IL-8 was the single best
discriminator between groups (0.34 above 0.50). In com-
parison IL-5 and IL-23, the next best markers repre-
sented a 40% decrease in AUC (0.20 above 0.50). With
respect to the U statistic IL-8 and 23 were virtually
equivalent with the next best marker leading to a 20%decrease in reliability. The next 3 positions were occu-
pied by a combination of IL-2, IL-13, and IL-15 as well
as IFN-γ, TNF-α and TNF-β depending on the criterion
used. However, these corresponded to a greater than
50% reduction in the AUC and a 40% decrease in the U
statistic when compared to IL-8 and IL-5 respectively.
This ranking was slightly different when we corrected
for cross-correlation between cytokines by reweighting
the Z statistic using an alpha value of α=1 as described
above (2.3.2 of the Methods section). Once again IL-5, 8
and 23 were selected as the top ranking cytokines. The
next 3 positions were occupied by a combination of the
same cytokines as before with the exception that IL-15
was replaced by IL-6. Once again these corresponded to
a loss in performance of greater than 50% in both AUC
and U metrics when compared to IL-5 or IL-8.
A candidate cytokine-based signature for IM-induced
chronic fatigue
For all their merit individual cytokines are not without
their limitations as biomarkers. Their use in combin-
ation has the potential to improve classification perform-
ance by introducing immune context. Cytokines are not
expressed independently but instead their patterns arise
as a result of one or several basic immune processes act-
ing in concert. This limits the expression of cytokines to
specific patterns and deviation from these patterns may
Table 1 Individual Cytokines as Illness Markers
Ranked Features PI-CFS vs Ctrl** CC weight alpha=0
ROC AUC-0.50 Wilcoxon U statistic
IL-8 (pg/ml) 0.34 IL-5 0.31
IL-5 (pg/ml) 0.20 IL-23 0.30
IL-23 (pg/ml) 0.20 IL-8 0.24
IL-13 (pg/ml) 0.16 IFN-g 0.18
IL-2 (pg/ml) 0.16 TNFa 0.13
IL-15 (pg/ml) 0.14 TNFb 0.13
IL-17 (pg/ml) 0.13 IL-12p70 0.10
IL-6 (pg/ml) 0.10 IL-1b 0.07
IL-10 (pg/ml) 0.08 IL-1a 0.06
IFN-g (pg/ml) 0.07 IL-13 0.06
IL-4 (pg/ml) 0.07 IL-2 0.06
TNFb (pg/ml) 0.04 IL-15 0.04
IL-1a (pg/ml) 0.04 IL-17 0.04
IL-1b (pg/ml) 0.04 IL-4 0.03
TNFa (pg/ml) 0.03 IL-10 0.03
IL-12p70 (pg/ml) 0.01 IL-6 0.00
Ranked Features PI-CFS vs Ctrl** CC weight alpha=1.0
ROC AUC-0.50 Wilcoxon U statistic
IL-8 (pg/ml) 0.34 IL-5 0.31
IL-23 (pg/ml) 0.20 IL-8 0.24
IL-5 (pg/ml) 0.20 IL-23 0.30
IL-2 (pg/ml) 0.16 TNFb 0.13
IL-13 (pg/ml) 0.16 IFN-g 0.18
IL-6 (pg/ml) 0.10 TNFa 0.13
IL-17 (pg/ml) 0.13 IL-1a 0.06
IL-15 (pg/ml) 0.14 IL-12p70 0.10
IFN-g (pg/ml) 0.07 IL-2 0.06
IL-10 (pg/ml) 0.08 IL-1b 0.07
IL-4 (pg/ml) 0.07 IL-13 0.06
IL-1a (pg/ml) 0.04 IL-17 0.04
TNFb (pg/ml) 0.04 IL-15 0.04
IL-1b (pg/ml) 0.04 IL-10 0.03
TNFa (pg/ml) 0.03 IL-4 0.03
IL-12p70 (pg/ml) 0.01 IL-6 0.00
Relative rank of individual cytokines based on their classification performance
as evaluated by the area (AUC) under the receiver operating characteristic
(ROC) curve and the Wilcoxon U statistic. Values without cross-correlation
adjustment (CC Weight α=0) and with full cross-correlation adjustment are
shown (CC weight α=1).
** Note: values were not log transformed since ROC rank is non-parametric.
Figure 2 A Cytokine-based Subject Classification. Linear
classification scores for the assignment of subjects to the overall
PI-CFS group obtained using the simple linear classifier 0 > B0 + B*X
where X is the normalized concentration of cytokines IL-2, 6, 8 23
and IFN-γ.
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question may still be within expected ranges when con-
sidered individually. Not only is analysis of co-
expression more representative of the underlying biology
but from a purely statistical perspective, these measure-
ments are subject to various levels of noise and the useof a weighted average score across several cytokines pro-
mises to be much more reliable. Indeed, in our analysis
a minimal set of 5 cytokines was necessary to satisfy the
criterion of better than 80% accuracy at a confidence
level of 0.95 (Figure 2). The subset of 5 cytokines that
maximized the performance of a simple linear classifica-
tion model with minimal redundancy consisted of IL-2,
IL-6, IL-8, IL-23 and IFN-γ. As shown in Table 2 this
classification model supported a specificity of 88% at a
sensitivity of 94% (PPV= 0.85, NPV= 0.95) when applied
to the training data of adolescent PI-CFS patients and
recovered controls. Only 7 of the 42 individual samples
received an inconclusive assignment when a minimal
confidence level of 0.95 was applied. In comparison clas-
sifiers constructed with cytokines best ranked on the
basis of their individual performance produced much
higher levels of uncertainty. For example the 5 cytokines
ranked best in terms of contribution to the AUC, namely
IL-8, IL-5, IL-2, IL-23 and IL-13, produced over 26 out
of 42 inconclusive class assignments at a confidence
threshold of 0.95. Adjusting further for the partial cor-
relation between these cytokines (collinearity) only
reduced this to 22 inconclusive class assignments. Simi-
larly a classification based on IL-5, IL-23, IL-8, IFN-γ
and TNF-β, ranked best on the basis of the U statistic,
produced 29 inconclusive assignments in the set of 42
individual samples. Once again 24 of these remained
after correction for correlation between cytokines (col-
linearity). The general performance characteristics for
these alternate models are summarized in Table 2.
Even though IL-5 ranked highly in terms of individual
performance it was not selected as a contributor to
the classification model. To explore this further we
Table 2 Performance Characteristics1 of Subject Classification using Cytokine Combinations
Optimal Linear model subset Top ranking AUC with CC correction Top ranking U statistic with CC correction
Classification based on
IL-2, 6, 8, 23, IFNg
Classification based on
IL-2, 5, 8, 13, 23
Classification based on IL-5,













Correct Rate 0.97 0.90 0.94 0.86 0.92 0.79
Error Rate 0.03 0.10 0.06 0.14 0.08 0.21
Inconclusive Rate 0.17 0.00 0.62 0.00 0.69 0.00
Classified Rate 0.83 1.00 0.38 1.00 0.31 1.00
Sensitivity 0.72 0.94 0.33 0.83 0.33 0.67
Specificity 0.88 0.88 0.38 0.88 0.25 0.88
Positive Predictive Value 0.81 0.85 0.29 0.83 0.25 0.80
Negative Predictive Value 0.81 0.95 0.43 0.88 0.33 0.78
Positive Likelihood 5.78 7.56 0.53 6.67 0.44 5.33
Negative Likelihood 0.32 0.06 1.78 0.19 2.67 0.38
Classification models based on random all-possible-subset selection of 5 cytokines as well as the top 5 ranking cytokines based on individual contribution to the
AUC and the U statistic.
1 Correct Rate is defined as (correctly classified samples)/ (all classified samples); Error rate as (incorrectly classified samples)/ (all classified samples); Inconclusive
Rate is defined as (non-classified samples) / (total number of samples); Classified rate is (classified samples) / (total number of samples); Sensitivity is defined as
(correctly classified positives) / (true positives); Specificity is (correctly classified negatives) / (true negatives); Positive Predictive Value is (correctly classified
positives) / (positive classified); Negative Predictive Value is (correctly classified negatives) / (negative classified); Positive Likelihood is Sensitivity / (1 – Specificity);
Negative Likelihood is (1 – Sensitivity) / Specificity.
Broderick et al. Journal of Translational Medicine 2012, 10:191 Page 7 of 11
http://www.translational-medicine.com/content/10/1/191examined the correlation of IL-5 with other cytokines.
The cross-correlation patterns existing between cyto-
kines in the PI-CFS patient set as well as in the recov-
ered control group are presented in Additional file 1:
Table S4. These indicate strong and significant (p < 0.05)
correlations between IL-5 and IL-23 as well as with IFN-
γ in the PI-CFS patient set (r = 0.65, 0.77; p < 0.01).
Truncation of these terms and substitution with IL-5
into the random subset model was explored as a strategy
for alleviating these redundancies. In all cases classifica-
tion performance was significantly reduced (Additional
file 1: Table S5). This suggests that IL-23 and IFN-γ are
better suited than IL-5 to support class assignment
based on IL-2, 8 and 6.
In order to test the robustness of this combination of
cytokines, a stepwise selection algorithm was also ap-
plied to the same data. Stepwise selection produced a
linear classification model that was once again based on
a subset of 5 cytokines. In this sequential model-
building scheme, IL-6, 8 and 23 were again chosen as
significant markers of PI-CFS. Also selected were IL-1a
and IL-13. Together theses 5 cytokines supported the
assignment of samples to their correct diagnostic class
with a specificity of 94% at a sensitivity of 91% (PPV=
0.95, NPV= 0.89) (Table 3). Using the consensus terms
shared by both the all-possible-subsets (Table 2) and
stepwise models leads to a classification model based onIL-6, 8 and 23 alone. This reduced consensus model
supported a specificity of 88% at a sensitivity of 83%
(PPV= 0.91, NPV= 0.80) (Table 3). Because samples
from 4 PI-CFS patients were unavailable for analysis a
set of simulations was used to test the stability of the
above-mentioned models to inclusion of these subjects.
In a worst-case scenario these patients were included in
the analysis and assigned cytokine profiles selected ran-
domly from the set of healthy normal profiles. With
each random assignment a stepwise regression model
was constructed. In 50 repeated assignments, IL-8 was
unanimously selected in all regression models, while IL-
6 ranked second with recruitment into 41 of 50 models
(Additional file 1: Table S6). Of the initial classification
model IL-6, 8 and 23 were selected by two different re-
gression algorithms with simulations showing IL-6 and 8
to be particularly robust choices for this data.
Discussion
In this work we studied a population of adolescents that
developed CFS as a sequela of monospot-positive IM
and compared them to control subjects who recovered
normally from the same infection. Approximately 4% of
subjects (or 13 individuals) diagnosed with IM fit the
case definition for CFS at 24 months, a number consist-
ent with other prospective studies of infectious onset
CFS [12,13]. In comparing the concentrations of 16















Correct Rate 0.93 0.86 0.79
Error Rate 0.07 0.14 0.21
Inconclusive Rate 0.00 0.00 0.00
Classified Rate 1.00 1.00 1.00
Sensitivity 0.92 0.83 0.79
Specificity 0.94 0.89 0.78
Positive Predictive Value 0.96 0.91 0.83
Negative Predictive Value 0.89 0.80 0.74
Positive Likelihood 16.50 7.50 3.56
Negative Likelihood 0.09 0.19 0.27
Performance of linear classification models based on (i) a stepwise selection of
IL-1a, 6, 8, 13 and 23, (ii) the intersecting subset of IL-6, 8 and 23 found in
both stepwise and all-possible-subsets models and (iii) a core selection of IL-6
and 8, the two most robust choices based on simulations with random data
substitutions.
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found significantly different levels of IL-8, IL-23 and
possibly IL-2 and IL-5 in plasma samples from CFS
patients. Increased IL-8 and decreased IL-5 is a pattern
also seen asthma [34] and in B cell chronic lymphocytic
leukemia (B-CLL) [35]. Most striking were differences in
IL-23, a cytokine expressed by dendritic cells and macro-
phages. Though not required for the generation of Th17
cells from naïve CD4+ T cells, IL-23 is nonetheless es-
sential for the full and sustained differentiation of the
Th17 cell subset [36]. Median concentration of this cyto-
kine was significantly lower in patients with CFS than in
recovered controls. IL-23 expression is highly inducible
in PHA-stimulated CD4+ cells, in particular when
primed with IFN-γ, suggesting a potential role for IL-23
in Th1 response [37]. We found decreased expression of
IL-23 in CFS patients despite comparable levels of IFN-γ.
In addition we found levels of IL-17 to be similar despite
elevated levels of known antagonist IL-2 [38]. Consistent
with this, our previous analysis of cytokine expression in
a population of adult subjects with CFS of unknown eti-
ology [27] indicated an abnormally subdued IL-23/Th17/
IL-17 response to elevated levels of known inducers
IL-1b and IL-6 [39].
The above-mentioned discrepancies emphasize the im-
portance of immune context. Indeed it was necessary to
use the combined expression of 5 cytokines to support a
robust separation of patients from recovered controls.
Ultimately the context linking the expression of these
cytokines arises from one or several basic immuneprocesses acting in concert. Here the choice of cytokines
in both the all-possible-subsets and stepwise regression
models is interesting in that the majority of these are ei-
ther directly or indirectly related to Th17 response [39].
In this analysis IL-6, 8 and 23 were selected by two differ-
ent statistical approaches, with IL-1a, IL-2 and IFN-γ
also selected in one model or the other. It is interesting
to note that neither IL-1a, nor IL-6 or IFN-γ were differ-
entially expressed across groups even though they con-
tributed significantly to the classification of these
subjects. IL-1, 6 and 23 are known inducers of Th17 re-
sponse, which in turn is a producer of IFN-γ [39]. Con-
versely IL-2 is generally known as a Th17 antagonist [38].
Liu et al. (2007) [40] describe a mechanism by which
IL-1 induces the production of IL-23 via NF-kappa B acti-
vation, which in turn promotes the production of IL-6 and
8 in human fibroblast-like synoviocytes from rheumatoid
arthritis patients. Though this is still poorly understood, re-
cent evidence in animal models supports a role for EBV
and EBV-inducible genes in the pathogenic modulation of
Th17 response [41,42]. This may involve TLR9 which has
been shown recently to play a significant role in the recog-
nition of EBV by primary dendritic cells (DC), as indicated
by a marked inhibitory effect on their synthesis of IFN-α,
IL-6, and IL-8 [43]. Collectively the current analysis, as well
as results from our previous work [27], suggests that
illness-specific differences in the regulation of Th17 re-
sponse may be a shared component in a significant subset
of CFS cases.
When comparing this work with results from other
studies it is important to remember the type of sample
and the specific patient population studied. For example,
recent work by Brenu et al. (2011) [44] demonstrated
higher levels of IL-10, IFN-γ and TNF-α in CFS. How-
ever this was measured in mitogen-stimulated CD4+ cell
cultures not in plasma. Similar in vitro protocols were
used in earlier work by Amel Kashipaz et al. (2003) [45]
and Skowera et al. (2004) [46]. Using the same sample
type and laboratory protocol applied here, we recently
reported higher levels of IL-5 and lower levels of IL-8 in
CFS subjects compared to healthy controls, while levels
of IL-23 showed little difference [27]. However both the
work of Broderick et al. (2010) [27] and Brenu et al.
(2011) [44] were conducted in a much broader CFS pa-
tient population where the illness trigger was not uni-
form. In addition the control population consisted of
otherwise healthy individuals not individuals recovering
from acute infection. Estimates of the number of
patients with CFS who can date their illness to a specific
(presumably infectious) acute illness range from 20-
90%, with the highest percentages being recorded in
adolescent populations [8,47-53]. Accordingly our
current results align closely with those of another study
conducted specifically in a post-infectious patient
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authors found no differences in the concentrations of
IL-1b, IL-2, IL-4, IL-6, IL-10, IL-12, TNF-α, and IFN-γ
analyzed in serum. With the possible exception of
elevated IL-2, we also did not find differences in the
levels of these cytokines. Levels of IL-5, 8 and 23 were
not measured in this earlier study.
Limitations of our current study include the fact that it
reports on a small cohort. This is important when con-
sidering the general applicability of our statistical classifi-
cation model in particular. The hope is that this subset of
subjects is somewhat representative of a larger PI-CFS
patient population. CFS is well known for its heteroge-
neous presentation; however it can be argued that much
of this is the result of varied etiology and unknown trig-
gers. Our results are derived from a prospective study
and constitute an important first look at the molecular
phenotyping of persistent fatigue in a cohort with a uni-
form and known infectious trigger; namely infectious
mononucleosis. While this trigger does not explain all
presentations of CFS, it does represent a significant sub-
set of patients, in particular in the pediatric population.
Moreover though specific to the EBV pathogen, elements
presented here may also be of relevance to other forms
of CFS with an infectious etiology. Constraints such as
these further emphasize the importance of prospective
studies and the need for much larger initiatives of this
type in this and related patient populations.
Conclusion
In conclusion, the co-expression profile of 5 of 16 cyto-
kines measured in the plasma of subjects recruited in a 2-
year prospective study of mononucleosis-induced chronic
fatigue syndrome readily discriminates cases from recov-
ered control subjects and describes an atypical immune
response in these individuals. In particular, irregular pat-
terns of co-expression in IL-6, 8 and 23 were identified
using two distinct statistical methodologies. These differ-
ences were especially evident when cast in the context of
IL-1a, IL-2 and IFN-γ. This evidence points to a possible
dysregulation of the innate system’s priming of the appro-
priate adaptive Th17 response in these subjects.
Additional file
Additional file 1: Table S1. Assay performance measures for
chemiluminescent determination of cytokine concentration. Described
are the calibration standard sample concentrations used and the
corresponding mean estimated concentration (pg/ml) based on
duplicate measurements for each of the 16 cytokine species. Table S2.
Significance of subject-to-subject changes in cytokine expression when
compared with replicate error based on parametric a one-way ANOVA
(ANOVA-1) and the non-parametric Kruskal-Wallis test. All concentrations
were log-transformed. Table S3. Summary statistics (mean, standard
deviation, median and median absolute deviation from the median -
MADM) and statistical significance of the change in Chalder fatigue scoreand in the expression in 16 cytokines measured in plasma for the PI-CFS
group compared to control subjects based on the standard two-tailed
t-test and the non-parametric Wilcoxon test. Table S4. Pearson correlation
coefficient r and associated null probability (p-value) for co-expression
patterns existing between cytokines in the PI-CFS patient group and in
the group of recovering control subjects. Table S5. Performance of
alternative linear classification models were IL-5 has been substituted for
IL-23 or IFN-γ or both to resolve collinearity issues with the latter by
simple truncation. Statistics are shown for classification performance
where a 90% confidence in assignment is imposed (Linear cw 90% conf.)
and where the score alone is considered (Linear uncorrected). Table S61.
Sensitivity study of n=4 absent PI-CFS profiles: in order to assess the
impact of the n=4 sets of duplicate cytokine profiles missing from the
n=13 PI-CFS subject group, a series of 20, 50 and 100 simulation
experiments were conducted. In each experiment a random set of n=4
sets of duplicate samples were selected from the recovered control data
and added to the PI-CFS set. A stepwise regression model was then used
to select discriminating cytokines based on this artificially augmented
data. Below is the frequency with which each cytokine was selected in
the 50 regression models.Competing interests
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